

## Remarks

### Amendments to the Claims

The amendments to the claims do not add new matter. Claims 1, 8, and 10-17 are amended to recite representative sequence identifiers, which are disclosed in the specification as follows:

- SEQ ID NO:3 , page 5;
- SEQ ID NO:20, page 21;
- SEQ ID NO:25, page 23;
- SEQ ID NO:48, page 32;
- SEQ ID NO:51, page 33; and
- SEQ ID NO:54, page 34.

New claims 22 also recite representative sequence identifiers, which are disclosed in the specification at the following pages:

- SEQ ID NO:28, page 25;
- SEQ ID NO:33, page 27;
- SEQ ID NO:40, page 30;
- SEQ ID NO:43, page 30; and
- SEQ ID NO:38, page 29.

Claims 10, 13, 15 are amended to refer to some of the recited antigens by their protein names; new claims 22-26 also recite protein names. These names are disclosed in the specification as follows:

- C5a peptidase (GBS 276), page 23;
- UDP-N-acetylmuramoylalanine-D-glutamate ligase (Mur D) (GBS 305),

page 26;

- surface immunogenic protein (sip) (GBS 322), page 28;<sup>1</sup>
- pyruvate kinase (pyk) (GBS 29);
- Sat D (GBS 338), page 30; and
- cylI (GBS 361), page 31.

Response to Restriction Requirement

Applicants elect (i) Group I (claims 1-17), (ii) SEQ ID NO:7 as the GBS80 fragment species, and (iii) the combination of GBS80 or SEQ ID NO:7 and GBS322 as the combination species. Claims 1-17 and new claims 22-30 read on the elected fragment species. Claims 1-17 and new claims 22-30 read on the elected combination species.

Respectfully submitted,

**BANNER & WITCOFF, LTD.**

/Lisa M. Hemmendinger/

Date: May 4, 2009

By:

Lisa M. Hemmendinger  
Registration No. 42,653

Customer No. 22907  
202-824-3000

---

<sup>1</sup> See also Brodeur *et al.*, "Identification of group B streptococcal Sip protein, which elicits cross-protective immunity," *Inf. Immun.* 68(10), 5610-8, Oct. 2000, which is provided with the Information Disclosure Statement filed with this response.